amiodarone has been researched along with Hemorrhage in 43 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary efficacy endpoint of stroke or systemic embolic event was significantly lower with LDE compared with warfarin in amiodarone treated patients vs." | 9.20 | Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. ( Antman, EM; Atar, D; Braunwald, E; Camm, AJ; Giugliano, RP; Heidbuchel, H; Murphy, SA; Ruff, CT; Steffel, J, 2015) |
| "Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients." | 9.01 | Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. ( Joung, B; Kim, HJ; Kim, IS; Kim, JY; Kim, TH; Lee, MH; Pak, HN; Uhm, JS; Yu, HT, 2019) |
| "Direct oral anticoagulants (DOACs) and amiodarone are widely used in the treatment of nonvalvular atrial fibrillation." | 8.98 | Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. ( Briceno, D; Di Biase, L; Ferrick, K; Fisher, J; Gross, JN; Kim, S; Krumerman, A; Lupercio, F; Maraboto, C; Peltzer, B; Romero, J; Villablanca, P, 2018) |
| "Amiodarone is a commonly used pharmacotherapy in patients with atrial fibrillation (AF), with a potential for drug-drug interactions with direct oral anticoagulants (DOACs)." | 8.31 | Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. ( Andrade, JG; Austin, PC; Caswell, J; Crystal, E; Jackevicius, CA; Ko, DT; Michael, F; Qiu, F; Shurrab, M; Singh, SM; Tu, K, 2023) |
| "Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding." | 8.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "The purpose of this study was to analyse the effects of demographic factors, clinical factors, and genetic polymorphisms of related gene loci on warfarin bleeding-related complications in the Han population." | 8.12 | Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin. ( Chen, W; Fu, J; Jiang, S; Lv, M; Wu, T; Xia, X; Zhang, J, 2022) |
| "To investigate whether co-administration of antiarrhythmic dronedarone and anticoagulant rivaroxaban would increase the risks of hemorrhage after atrial fibrillation (AF) ablation." | 8.12 | Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation. ( Cai, S; Liu, W; Pan, Y; Sun, P; Wang, M; Zhang, P; Zhao, Q, 2022) |
| "Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm." | 8.02 | Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. ( Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021) |
| "Median trough plasma concentration of dabigatran in our study was observed to be similar to median trough plasma concentration of dabigatran at a dose of 150 mg bid without concomitant dronedarone in earlier studies with low reported rate of bleeding and thrombosis." | 7.81 | Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice. ( Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M, 2015) |
| "A patient with mechanical heart valves developed bleeding, after the introduction of amiodarone and azithromycin." | 7.70 | Bleeding complication during coumarin therapy due to amiodarone and azithromycin. ( Bharat, V; Mohanty, B, 2000) |
| "Amiodarone, a cardiac antiarrhythmic agent, has been associated with the development of interstitial pulmonary fibrosis in patients receiving prolonged therapy with the drug." | 7.67 | Amiodarone-induced pulmonary fibrosis in hamsters. ( Cantor, JO; Cerreta, JM; Mandl, I; Osman, M; Suarez, R; Turino, GM, 1984) |
| "Diffuse alveolar hemorrhage is a rare reaction, with few case reports documented in the literature since amiodarone became widely used in the early 1980s." | 5.38 | A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. ( Bennett, S; Borders, CW; Claassen, SL; Mount, C, 2012) |
| " The primary efficacy endpoint of stroke or systemic embolic event was significantly lower with LDE compared with warfarin in amiodarone treated patients vs." | 5.20 | Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. ( Antman, EM; Atar, D; Braunwald, E; Camm, AJ; Giugliano, RP; Heidbuchel, H; Murphy, SA; Ruff, CT; Steffel, J, 2015) |
| "Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients." | 5.01 | Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. ( Joung, B; Kim, HJ; Kim, IS; Kim, JY; Kim, TH; Lee, MH; Pak, HN; Uhm, JS; Yu, HT, 2019) |
| "Direct oral anticoagulants (DOACs) and amiodarone are widely used in the treatment of nonvalvular atrial fibrillation." | 4.98 | Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. ( Briceno, D; Di Biase, L; Ferrick, K; Fisher, J; Gross, JN; Kim, S; Krumerman, A; Lupercio, F; Maraboto, C; Peltzer, B; Romero, J; Villablanca, P, 2018) |
| "Increased bleeding risk was found associated with concurrent prescription of rivaroxaban and amiodarone." | 4.31 | Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population. ( Chan, ECY; Cheong, EJY; Kojodjojo, P; Wang, Z, 2023) |
| "Amiodarone is a commonly used pharmacotherapy in patients with atrial fibrillation (AF), with a potential for drug-drug interactions with direct oral anticoagulants (DOACs)." | 4.31 | Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. ( Andrade, JG; Austin, PC; Caswell, J; Crystal, E; Jackevicius, CA; Ko, DT; Michael, F; Qiu, F; Shurrab, M; Singh, SM; Tu, K, 2023) |
| "Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding." | 4.31 | Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. ( Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E, 2023) |
| "The purpose of this study was to analyse the effects of demographic factors, clinical factors, and genetic polymorphisms of related gene loci on warfarin bleeding-related complications in the Han population." | 4.12 | Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin. ( Chen, W; Fu, J; Jiang, S; Lv, M; Wu, T; Xia, X; Zhang, J, 2022) |
| "To investigate whether co-administration of antiarrhythmic dronedarone and anticoagulant rivaroxaban would increase the risks of hemorrhage after atrial fibrillation (AF) ablation." | 4.12 | Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation. ( Cai, S; Liu, W; Pan, Y; Sun, P; Wang, M; Zhang, P; Zhao, Q, 2022) |
| "Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm." | 4.02 | Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. ( Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021) |
| "Amiodarone inhibits warfarin metabolism and is associated with major bleeding during warfarin therapy." | 3.96 | The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study. ( Brown, JR; Hennessy, S; Miano, TA; Shashaty, MGS; Yang, W; Zuppa, A, 2020) |
| "Median trough plasma concentration of dabigatran in our study was observed to be similar to median trough plasma concentration of dabigatran at a dose of 150 mg bid without concomitant dronedarone in earlier studies with low reported rate of bleeding and thrombosis." | 3.81 | Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice. ( Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M, 2015) |
| " He had been on amiodarone for atrial fibrillation and developed hemorrhagic manifestations due to factor V inhibitors within a few months of initiating amiodarone therapy." | 3.78 | A rare case of factor V inhibitor in a patient on amiodarone therapy. ( Lipshitz, J; Patel, D; Shreenivas, AV, 2012) |
| "Authors describe a case of drug interaction between amiodarone and warfarin in 66-year-old man with recurrent atrial fibrillation." | 3.72 | [Long-term drug interaction of warfarin with amiodarone]. ( Hirmerová, J; Mádr, T; Suchý, D, 2003) |
| "A patient with mechanical heart valves developed bleeding, after the introduction of amiodarone and azithromycin." | 3.70 | Bleeding complication during coumarin therapy due to amiodarone and azithromycin. ( Bharat, V; Mohanty, B, 2000) |
| "Amiodarone, a cardiac antiarrhythmic agent, has been associated with the development of interstitial pulmonary fibrosis in patients receiving prolonged therapy with the drug." | 3.67 | Amiodarone-induced pulmonary fibrosis in hamsters. ( Cantor, JO; Cerreta, JM; Mandl, I; Osman, M; Suarez, R; Turino, GM, 1984) |
| "Stroke and systemic thromboembolism are serious problems for patients with atrial fibrillation (AF), but their incidence can be substantially reduced by appropriate anticoagulation." | 2.71 | Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. ( Corley, SD; DiMarco, JP; Flaker, G; Greene, HL; Mitrani, G; Nemeth, M; Rosenfeld, LE; Safford, RE; Waldo, AL, 2005) |
| "Amiodarone is an antiarrhythmic agent that is used commonly in clinical practice." | 1.51 | Amiodarone-induced diffuse alveolar haemorrhage: a rare but potentially life-threatening complication of a commonly prescribed medication. ( Abdullah, HMA; Khan, UI; Saeed, J; Waqas, QA, 2019) |
| " Objectives An investigation of how initiation of amiodarone affects the anticoagulant effect and dosing of warfarin, using data from three nationwide registries." | 1.46 | The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. ( Andersson, ML; Holm, J; Lindh, JD; Mannheimer, B, 2017) |
| "Recent infection was present in 40." | 1.39 | Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. ( Ajrouche, R; Al-Hajje, A; Awada, S; El-Helou, N; Rachidi, S; Salameh, P; Zein, S, 2013) |
| "Diffuse alveolar hemorrhage is a rare reaction, with few case reports documented in the literature since amiodarone became widely used in the early 1980s." | 1.38 | A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. ( Bennett, S; Borders, CW; Claassen, SL; Mount, C, 2012) |
| " Patients received both amiodarone and warfarin for at least 1 year, and the dosage of warfarin was adjusted as clinically necessary to achieve an international normalized ratio of 2 to 3." | 1.31 | Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. ( Bauman, JL; Sanoski, CA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.30) | 18.7374 |
| 1990's | 3 (6.98) | 18.2507 |
| 2000's | 11 (25.58) | 29.6817 |
| 2010's | 15 (34.88) | 24.3611 |
| 2020's | 10 (23.26) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, X | 1 |
| Fu, J | 1 |
| Wu, T | 1 |
| Chen, W | 1 |
| Jiang, S | 1 |
| Lv, M | 1 |
| Zhang, J | 1 |
| Wang, Z | 1 |
| Cheong, EJY | 1 |
| Kojodjojo, P | 1 |
| Chan, ECY | 1 |
| Zhang, P | 1 |
| Wang, M | 1 |
| Liu, W | 1 |
| Sun, P | 1 |
| Cai, S | 1 |
| Pan, Y | 1 |
| Zhao, Q | 1 |
| Shurrab, M | 1 |
| Jackevicius, CA | 1 |
| Austin, PC | 1 |
| Tu, K | 1 |
| Qiu, F | 1 |
| Singh, SM | 1 |
| Crystal, E | 1 |
| Caswell, J | 1 |
| Michael, F | 1 |
| Andrade, JG | 1 |
| Ko, DT | 1 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Stein, CM | 1 |
| Smalley, W | 1 |
| Zimmerman, E | 1 |
| Dupont, WD | 1 |
| Hung, AM | 1 |
| Daugherty, JR | 1 |
| Dickson, AL | 1 |
| Murray, KT | 1 |
| Favre-Bulle, T | 1 |
| Saeed, J | 1 |
| Waqas, QA | 1 |
| Khan, UI | 1 |
| Abdullah, HMA | 1 |
| Miano, TA | 1 |
| Yang, W | 1 |
| Shashaty, MGS | 1 |
| Zuppa, A | 1 |
| Brown, JR | 1 |
| Hennessy, S | 1 |
| Matos, JD | 1 |
| McIlvaine, S | 1 |
| Grau-Sepulveda, M | 1 |
| Jawitz, OK | 1 |
| Brennan, JM | 1 |
| Khabbaz, KR | 1 |
| Sellke, FW | 1 |
| Yeh, R | 1 |
| Zimetbaum, P | 1 |
| Papanikolaou, IC | 1 |
| Makou, I | 1 |
| Markatis, E | 1 |
| Chiou, WR | 1 |
| Huang, CC | 1 |
| Lin, PL | 1 |
| Chuang, JY | 1 |
| Liu, LY | 1 |
| Su, MI | 1 |
| Liao, FC | 1 |
| Chen, CY | 1 |
| Kuo, JY | 1 |
| Tsai, CT | 1 |
| Wu, YJ | 1 |
| Lee, YH | 1 |
| Lupercio, F | 1 |
| Romero, J | 1 |
| Peltzer, B | 1 |
| Maraboto, C | 1 |
| Briceno, D | 1 |
| Villablanca, P | 1 |
| Ferrick, K | 1 |
| Gross, JN | 1 |
| Kim, S | 1 |
| Fisher, J | 1 |
| Di Biase, L | 1 |
| Krumerman, A | 1 |
| Kim, IS | 1 |
| Kim, HJ | 1 |
| Yu, HT | 1 |
| Kim, TH | 1 |
| Uhm, JS | 1 |
| Kim, JY | 1 |
| Joung, B | 1 |
| Lee, MH | 1 |
| Pak, HN | 1 |
| El-Helou, N | 1 |
| Al-Hajje, A | 1 |
| Ajrouche, R | 1 |
| Awada, S | 1 |
| Rachidi, S | 1 |
| Zein, S | 1 |
| Salameh, P | 1 |
| Lam, J | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Pullenayegum, EM | 1 |
| Kearon, C | 1 |
| Spencer, FA | 1 |
| Paterson, M | 1 |
| Zheng, H | 1 |
| Holbrook, AM | 1 |
| Semenas, E | 2 |
| Sharma, HS | 1 |
| Wiklund, L | 1 |
| Zoerner, F | 1 |
| Aguilar, C | 1 |
| Mochalina, N | 1 |
| Juhlin, T | 1 |
| Platonov, PG | 1 |
| Svensson, PJ | 1 |
| Wieloch, M | 1 |
| Steffel, J | 1 |
| Giugliano, RP | 1 |
| Braunwald, E | 1 |
| Murphy, SA | 1 |
| Atar, D | 1 |
| Heidbuchel, H | 1 |
| Camm, AJ | 1 |
| Antman, EM | 1 |
| Ruff, CT | 1 |
| Holm, J | 1 |
| Lindh, JD | 1 |
| Andersson, ML | 1 |
| Mannheimer, B | 1 |
| Cadiou, G | 1 |
| Varin, R | 1 |
| Levesque, H | 1 |
| Grassi, V | 1 |
| Benichou, J | 1 |
| Tiret, I | 1 |
| Dieu, B | 1 |
| Lecam-Duchez, V | 1 |
| Borg, JY | 1 |
| Muller, JM | 1 |
| Benhamou, Y | 1 |
| Marie, I | 1 |
| Tanawuttiwat, T | 1 |
| Harindhanavudhi, T | 1 |
| Hanif, S | 1 |
| Sahloul, MZ | 1 |
| Borders, CW | 1 |
| Bennett, S | 1 |
| Mount, C | 1 |
| Claassen, SL | 1 |
| Shreenivas, AV | 1 |
| Lipshitz, J | 1 |
| Patel, D | 1 |
| Blasco, LM | 1 |
| Lee, J | 1 |
| Lee, B | 1 |
| Kim, K | 1 |
| Ahn, H | 1 |
| Suh, O | 1 |
| Lee, M | 1 |
| Shin, W | 1 |
| Hirmerová, J | 1 |
| Suchý, D | 1 |
| Mádr, T | 1 |
| Siguret, V | 1 |
| Esquirol, C | 1 |
| Debray, M | 1 |
| Gouin, I | 1 |
| Andreux, JP | 1 |
| Pautas, E | 1 |
| DiMarco, JP | 1 |
| Flaker, G | 1 |
| Waldo, AL | 1 |
| Corley, SD | 1 |
| Greene, HL | 1 |
| Safford, RE | 1 |
| Rosenfeld, LE | 1 |
| Mitrani, G | 1 |
| Nemeth, M | 1 |
| Singh, S | 1 |
| Iskandar, SB | 1 |
| Abi-Saleh, B | 1 |
| Keith, RL | 1 |
| Byrd, RP | 1 |
| Roy, TM | 1 |
| Tsukada, YT | 1 |
| Kishida, H | 1 |
| Cantor, JO | 1 |
| Osman, M | 1 |
| Cerreta, JM | 1 |
| Suarez, R | 1 |
| Mandl, I | 1 |
| Turino, GM | 1 |
| Lee, HS | 1 |
| Quinn, T | 1 |
| Boyle, RM | 1 |
| Iskander, S | 1 |
| Raible, DG | 1 |
| Brozena, SC | 1 |
| Gaitanaru, DM | 1 |
| Ayala, G | 1 |
| Iskandrian, AE | 1 |
| Bharat, V | 1 |
| Mohanty, B | 1 |
| Sanoski, CA | 1 |
| Bauman, JL | 1 |
| O'Leary, TG | 1 |
| Kotecha, B | 1 |
| Rothera, MP | 1 |
| Caraco, Y | 2 |
| Chajek-Shaul, T | 1 |
| Fondevila, C | 1 |
| Meschengieser, S | 1 |
| Lazzari, MA | 1 |
| Raveh, D | 1 |
| Flugelman, M | 1 |
| Raz, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000556] | Phase 3 | 0 participants | Interventional | 1995-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for amiodarone and Hemorrhage
| Article | Year |
|---|---|
Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Drug | 2018 |
Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anticoagulants; ATP Binding Cassette Transporter, Sub | 2019 |
Antithrombotic therapy in a patient with mild haemophilia A and atrial fibrillation: case report and brief review of the literature.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Disease Management; Dronedar | 2015 |
[Adverse effects of cardiovascular agents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Brugada Syndrome; Drug Interactions; Fibrinolyti | 2007 |
2 trials available for amiodarone and Hemorrhage
| Article | Year |
|---|---|
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Hemorrhage; H | 2015 |
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Mod | 2005 |
37 other studies available for amiodarone and Hemorrhage
| Article | Year |
|---|---|
Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Apolipoproteins E; Asian People; Bo | 2022 |
Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population.
Topics: Aged; Amiodarone; Hemorrhage; Humans; Kidney; Renal Insufficiency; Rivaroxaban | 2023 |
Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Hemorrhage; | 2022 |
Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged, 80 and over; Amiodarone; Anticoagulants; Atrial Fibrillation; Cas | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; | 2023 |
Topics: Amiodarone; Hemorrhage; Humans | 2023 |
Amiodarone-induced diffuse alveolar haemorrhage: a rare but potentially life-threatening complication of a commonly prescribed medication.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Diagnosis, Differential; Female; Hemorrhage; Humans; Lung | 2019 |
The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Co | 2020 |
Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Canada; Clinical Deci | 2021 |
Amiodarone and diffuse alveolar hemorrhage.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cough; Dyspnea; Female; Hemorrhage; Humans; Lung Diseases; | 2020 |
Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2021 |
Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Anti-Inflammatory Agen | 2013 |
Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone.
Topics: Aged; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Cohort Studies; Drug Synergism | 2013 |
Adrenaline increases blood-brain-barrier permeability after haemorrhagic cardiac arrest in immature pigs.
Topics: Amiodarone; Animals; Blood-Brain Barrier; Capillary Permeability; Cardiopulmonary Resuscitation; Cer | 2014 |
Resuscitation with amiodarone increases survival after hemorrhage and ventricular fibrillation in pigs.
Topics: Amiodarone; Animals; Antidiuretic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; | 2014 |
Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.
Topics: Aged; Amiodarone; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Dr | 2015 |
The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Blood Coagulatio | 2017 |
Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Blood Coagulation Disorde | 2008 |
Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Fatal Outcome; Hemorrhage; Humans; Lung Di | 2010 |
A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Fatal Outcome; Hemorrh | 2012 |
A rare case of factor V inhibitor in a patient on amiodarone therapy.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Coagulation Tests; | 2012 |
Trepopnea due to amiodarone-induced diffuse alveolar hemorrhage.
Topics: Acenocoumarol; Aged; Amiodarone; Anemia; Anti-Arrhythmia Agents; Anticoagulants; Dyspnea; Hemoptysis | 2013 |
Factors affecting warfarin therapy following cardiac valve surgery.
Topics: Adult; Amiodarone; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Ethnicity; F | 2002 |
Interactions between amiodarone and vitamin K antagonists.
Topics: Amiodarone; Anticoagulants; Drug Interactions; France; Hemorrhage; Humans; Vitamin K; Warfarin | 2003 |
[Long-term drug interaction of warfarin with amiodarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Drug Interactions; He | 2003 |
[Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey].
Topics: 4-Hydroxycoumarins; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agen | 2003 |
Amiodarone-induced pulmonary hemorrhage.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Hemorrhage; Humans; Lung Diseas | 2006 |
Amiodarone-induced alveolar hemorrhage.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Hemorrhage; Humans; Lung Diseases; Ma | 2006 |
Amiodarone-induced pulmonary fibrosis in hamsters.
Topics: Amiodarone; Animals; Benzofurans; Cricetinae; Hemorrhage; Inflammation; Lung; Lung Diseases; Mesocri | 1984 |
Safety of thrombolytic treatment in patients with central venous cannulation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Catheterization, Central Venous; Contraindications; Fema | 1995 |
Acute alveolar hemorrhage and orthodeoxia induced by intravenous amiodarone.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Biopsy; Hemorrhage; Humans; Hypoxia; Lung Disease | 1999 |
Bleeding complication during coumarin therapy due to amiodarone and azithromycin.
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Azithromycin; Coumarins; Drug Interactions; Fatal O | 2000 |
Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy.
Topics: Aged; Amiodarone; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fe | 2002 |
Upper airway obstruction secondary to anticoagulant induced haemorrhage necessitating a tracheostomy.
Topics: Aged; Aged, 80 and over; Airway Obstruction; Amiodarone; Anticoagulants; Drug Interactions; Female; | 1990 |
The incidence and clinical significance of amiodarone and acenocoumarol interaction.
Topics: Acenocoumarol; Aged; Amiodarone; Drug Interactions; Female; Hemorrhage; Humans; Male; Middle Aged | 1989 |
Amiodarone potentiates acenocoumarin.
Topics: Acenocoumarol; Administration, Oral; Amiodarone; Drug Synergism; Hemorrhage; Humans; Injections, Int | 1989 |
Enhanced anticoagulant effect of acenocoumarol induced by amiodarone coadministration.
Topics: Acenocoumarol; Aged; Amiodarone; Blood Coagulation Disorders; Drug Combinations; Drug Synergism; Fem | 1988 |